药物经济学与结果研究国际协会（ISPOR）关于美国价值评估框架的倡议：行业视角 - Suppr | 超能文献

ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.

作者信息

Burkholder Randy, Dougherty J Samantha, Neves Lauren A

机构信息

Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA.

Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA.

出版信息

Value Health. 2018 Feb;21(2):173-175. doi: 10.1016/j.jval.2017.12.001.

DOI:10.1016/j.jval.2017.12.001

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.药物经济学与结果研究国际协会（ISPOR）关于美国价值评估框架的倡议：行业视角

Value Health. 2018 Feb;21(2):173-175. doi: 10.1016/j.jval.2017.12.001.

2

ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.国际药效经济学与结果研究协会（ISPOR）关于美国价值评估框架的倡议：成本效益研究在美国保险公司决策中的应用。

Value Health. 2018 Feb;21(2):166-168. doi: 10.1016/j.jval.2017.12.004.

3

ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.药物经济学与结果研究国际协会（ISPOR）关于美国价值评估框架的倡议：探寻健康经济学的作用。

Value Health. 2018 Feb;21(2):171-172. doi: 10.1016/j.jval.2017.12.003.

4

ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.药物经济学与结果研究国际协会（ISPOR）的美国价值评估框架倡议：ISPOR和患者错失的机遇。

Value Health. 2018 Feb;21(2):169-170. doi: 10.1016/j.jval.2017.12.002.

5

An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].价值、视角与决策背景概述——一种卫生经济学方法：ISPOR 特别工作组报告 [2]

Value Health. 2018 Feb;21(2):124-130. doi: 10.1016/j.jval.2017.12.006.

6

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会（ISPOR）特别工作组报告的总结与建议[7]

Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.

7

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].目标、预算、阈值与机会成本——一种卫生经济学方法：一份药物经济学与结果研究协会（ISPOR）特别工作组报告[4]

Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.

8

Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].近期美国价值框架综述——一种卫生经济学方法：一份药物经济学与结果研究协会（ISPOR）特别工作组报告[6]

Value Health. 2018 Feb;21(2):155-160. doi: 10.1016/j.jval.2017.12.011.

9

A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].美国价值评估框架的健康经济学方法——引言：一份ISPOR特别工作组报告[1]

Value Health. 2018 Feb;21(2):119-123. doi: 10.1016/j.jval.2017.12.012.

10

Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].医疗保健价值的定义要素——一种卫生经济学方法：一份ISPOR特别工作组报告[3]

Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.

引用本文的文献

1

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies.医疗保健利益相关者对杜氏肌营养不良症疗法价值评估方法的看法。

J Multidiscip Healthc. 2024 Aug 29;17:4199-4212. doi: 10.2147/JMDH.S458181. eCollection 2024.

2

Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.利益相关者对ICER证据报告草案公众意见的参与情况分析。

Am Health Drug Benefits. 2020 Sep;13(4):136-142.